Erythroid Promoter Confines FGF2 Expression to the Marrow after Hematopoietic Stem Cell Gene Therapy and Leads to Enhanced Endosteal Bone Formation

Fibroblast growth factor-2 (FGF2) has been demonstrated to be a promising osteogenic factor for treating osteoporosis. Our earlier study shows that transplantation of mouse Sca-1(+) hematopoietic stem/progenitor cells that are engineered to express a modified FGF2 leads to considerable endosteal/tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Xianmei, Baylink, David J., Sheng, Matilda, Wang, Hongjie, Gridley, Daila S., Lau, K.-H. William, Zhang, Xiao-Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356341/
https://www.ncbi.nlm.nih.gov/pubmed/22629419
http://dx.doi.org/10.1371/journal.pone.0037569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356341/
https://www.ncbi.nlm.nih.gov/pubmed/22629419
http://dx.doi.org/10.1371/journal.pone.0037569

Ejemplares similares